Multicenter trial shows benefits of personalized dosimetry with Simplicit90Y

In this study, the benefits of personalized dosimetry using Simplicit90Y for patients undergoing SIRT treatment with TheraSphere® are shown in a randomized, multicenter, phase II trial. Comparing to standard dosimetry, personalized dosimetry significantly improved the objective response rate in patients with locally advanced hepatocellular carcinoma, which, in turns, is likely to improve outcomes in clinical practice.

https://pubmed.ncbi.nlm.nih.gov/33166497/